Literature DB >> 8617966

Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing.

P Gasque1, B P Morgan, J Legoedec, P Chan, M Fontaine.   

Abstract

The complement (C) system has previously been implicated in several diseases of muscle. We here report that human myoblasts or rhabdomyosarcoma cell lines spontaneously activate C through the classical pathway, causing release of anaphylatoxins and coating of myoblasts with opsonic C fragments but without causing cell killing. Survival of myoblasts is a consequence of the abundant expression of the membrane C regulatory molecules MCP and CD59, and neutralization of CD59 renders cells susceptible to C killing. The decay-accelerating factor was expressed at a very low level. Myoblasts and rhabdomyosarcoma lines also abundantly express the fluid-phase regulators C1-inhibitor, factor H, C4 binding protein, S-protein, and clusterin and secrete a soluble form of CD59. Expression of membrane and fluid-phase regulators is enhanced by either IFN-gamma or TNF-alpha. Although myoblasts resist C killing, spontaneous activation of C on these cells may have important consequences in inflammatory diseases of muscle where the generation of anaphylactic and opsonic fragments will recruit and activate inflammatory cells. C activation on myoblasts may also have consequences for the use of these cells as vehicles for gene delivery. Inhibition of C using soluble complement receptor I (sCR1) efficiently protected myoblasts from C attack in vitro, and this agent, already being tested in therapy of several C-mediated diseases, might be of value in inflammatory muscle disease and in improving the efficiency of gene delivery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617966

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Extraocular muscle is defined by a fundamentally distinct gene expression profile.

Authors:  J D Porter; S Khanna; H J Kaminski; J S Rao; A P Merriam; C R Richmonds; P Leahy; J Li; F H Andrade
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

Review 3.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

4.  Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA.

Authors:  Priya Londhe; Judith K Davie
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

5.  cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Authors:  J Khan; M L Bittner; L H Saal; U Teichmann; D O Azorsa; G C Gooden; W J Pavan; J M Trent; P S Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

6.  RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.

Authors:  Yuefang Zhou; Henry J Kaminski; Bendi Gong; Georgiana Cheng; Jason M Feuerman; Linda Kusner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-10       Impact factor: 4.799

Review 7.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.